ANTITUMOR TARGET CELL PRODUCT, METHOD FOR ITS PRODUCTION AND ITS APPLICATION Russian patent published in 2021 - IPC A61K35/14 A61K35/28 A61K35/36 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: invention relates to the field of medicine, namely oncology; it can be used for the antitumor target therapy and prevention of cancer and other malignant neoplasms. Biomedical cell product (hereinafter – BMCP) for the treatment and prevention of cancer and other malignant neoplasms contains autologous or immunocompatible allogeneic mononuclear cells (hereinafter – MNC) of mobilized human peripheral blood (component A) containing hematopoietic stem cells (hereinafter – HSC) with markers CD34+, CD45+ in the number of 1-2% of cells of the total number of MNC and mesenchymal stromal stem cells (hereinafter – MSSC) with markers CD10+, CD13+, CD44+, CD90+ (Thy-1), CD105+, CD34-, CD45- and CD117- in the number of 0.5-2% of cells of the total number of MNC, as well as a line of autologous or immunocompatible allogeneic neural stem cells (hereinafter – NSC) with a marker CD133+ (component B) and/or a line of autologous or immunocompatible allogeneic MSSC with markers CD10+, CD13+, CD44+, CD90+ (Thy-1), CD105+, CD34-, CD45- and CD117- (component C). Components B and C are transcriptomically modified by processing them with perturbagen, which leads to the formation of cell secretome of these components capable of blocking the intracellular integrin/focal adhesion signaling pathway in tumor and tumor stem cells. BMCP also contains an auxiliary agent in the form of sterile transfusion medium at following concentrations of cells per 1 ml of the auxiliary agent: component A (MNC) – 0.8×10⁶ – 4×10⁶ of cells; component B (NSC) – 4×10³ – 3.3×10⁵ of cells; component C (MSSC) – 0.5×10⁶ – 2×10⁶ of cells. A method for producing ex tempore BMCP and its application for the treatment and prevention of cancer and other malignant neoplasms are also disclosed.

EFFECT: group of inventions provides BMCP that is balanced by cell content and that has high antitumor efficiency.

12 cl, 2 dwg, 3 tbl, 2 ex